Availability |
Relative ease of manufacture making it economically viable across a range of healthcare systems |
Mechanism of uptake |
Innate affinity for areas of bone metastases or easily chelated with other species conferring such affinity |
Efficacy |
Response rates, with regard to pain, similar to or better than those seen with external beam radiotherapy |
Safety—patient |
Acceptable toxicity profile |
Safety—public |
Minimal radiation protection issues—avoiding isolation/inpatient treatment if possible |
Safety—environment |
Physical half-life allowing practical time from manufacture for delivery and administration but ensuring safe and timely decay within subject or shortly after excretion |